Compare First Trust Cloud Computing ETF (SKYY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs 10X Genomics Inc — how do they compare? First Trust Cloud Computing ETF trades at $171.97 (market cap $3.47B), while 10X Genomics Inc trades at $82 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 2.9× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 84 Days and 10X Genomics Inc for 92 Days on average.
| SKYY | TXG | |
|---|---|---|
Market Cap | $3.47B | $10.07B |
Volume | 176,159 | 5,657,286 |
52-Week High | $171.01 | $97.74 |
52-Week Low | $104.16 | $11.48 |
Typical Hold Time | 84 Days | 92 Days |
Sector | — | Health |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKYY, the First Trust Cloud Computing ETF, trades at $170.78, down 0.13% on the day but near its 52-week high. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The fund provides diversified exposure to the cloud computing sector, benefiting from AI adoption and digital transformation trends. Recent news highlights a new 52-week high and institutional activity, reflecting positive momentum.
The outlook for SKYY is favorable, driven by secular growth in cloud infrastructure and AI demand. Key opportunities include exposure to hyperscaler capex and data center investments without heavy concentration in mega-cap tech. Risks involve sector volatility, competitive pressures, and macroeconomic sensitivity. Analyst sentiment is constructive, with the ETF positioned to capitalize on long-term technology shifts.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
